Parents were more willing to allow their children to receive a vaccine against human papillomavirus (HPV) if they interacted with a chatbot powered by artificial intelligence (AI) compared with parents who received no information about the vaccine.
The chatbot’s effects faded after 45 days, suggesting the benefits were short-lived, according to a randomized controlled trial of 1,297 parents of children not yet immunized against HPV. The results were published last week in JAMA Network Open.
Traditional information had more lasting impact
The chatbot also performed no better than traditional public health materials, according to the clinical trial, which was led by researchers with the University of Pennsylvania’s computer and information science department. Public health materials, however, maintained a modest effect at 45 days.
The study measured self-reported likelihood of vaccinating a child against HPV within 12 months on a 100-point scale, with 0 indicating parents were extremely unlikely and 100 being extremely likely.
The trial was conducted online among adults in the United States, Canada, and the United Kingdom from March 3 to May 25, 2026. Researchers followed up with participants after 15 days and 45 days. All participants had at least one child eligible for HPV vaccination, which the American Academy of Pediatrics recommends for boys and girls aged 9 to 12.
“Well-designed public health messaging may match or exceed the impact of short chatbot conversations for HPV vaccine promotion,” the study authors concluded.